Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Fifteen colleges would be affected by the executive order; K-12 schools nationwide no longer have such a requirement. Meanwhile, hospitals and medical providers are feeling the strain of the nation's ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Valeo Financial Advisors LLC decreased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 62.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.

Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...